News

Pfizer criticised over delay in admitting drug's problems

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7472.935-a (Published 21 October 2004) Cite this as: BMJ 2004;329:935
  1. Jeanne Lenzer
  1. New York

    Pfizer delayed announcing negative data about its painkiller valdecoxib (Bextra), Curt Furberg, a member of the US Food and Drug Administration's Data Safety and Risk Management Advisory Committee, told the BMJ this week. When the company eventually presented its data to the FDA, it also left out important details, Dr Furberg alleges.

    Pfizer stood to gain by …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe